Biolife Solutions (BLFS) | Stock Overview & Key Data
Biolife Solutions Performance Comparison
Stock Range
Today's Range
Low: $26.10
High: $27.37
on October 8, 2025
52 Week Range
Low: $19.10
High: $29.55
on April 9, 2025
on January 30, 2025
All-Time High: $1,382.50 on November 4, 1991
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.3B
EPS
-0.40
P/E Ratio (TTM)
-60.73
Forward P/E
-93.93
P/B Ratio
3.62
PEG Ratio
2.28
Div. Yield
N/A
ROE
-5.66%
Beta
1.951
Debt to Equity
6.86
Financial Highlights
Profitability
Gross Margin
64.64%
Operating Margin
-4.41%
Profit Margin
-5.92%
Returns and Earnings
Return on Assets (TTM)
-0.80%
Return on Equity (TTM)
-5.66%
EBITDA
$5.6M
Net Income (TTM)
$-18.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.99
Quarterly Revenue Growth (YoY)
28.90%
Quarterly Earnings Growth (YoY)
-10.26%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Biolife Solutions BLFS | 1.26B Small-cap | 4.63% | 4.27% | 21.24% | 32.46% | 4.43% | 20.97% | 34.75% | -2.95% |
| Intuitive Surgical ISRG | 163.82B Large-cap | 2.29% | -4.66% | -15.02% | -2.08% | -14.49% | -7.57% | 144.78% | 78.60% |
| Becton, Dickinson BDX | 55.18B Large-cap | 1.57% | 1.23% | 11.05% | -3.44% | -14.38% | -18.00% | -13.69% | -16.12% |
| Lemaitre Vascular LMAT | 2.01B Mid-cap | 1.58% | -9.30% | 4.92% | 13.03% | -3.75% | -2.81% | 87.64% | 172.49% |
| AtriCure ATRC | 1.73B Small-cap | 2.48% | -2.56% | 10.91% | 14.60% | 15.39% | 26.01% | 4.78% | -13.79% |
| Azenta AZTA | 1.41B Small-cap | 2.06% | 9.37% | -3.82% | 21.21% | -35.59% | -28.84% | -17.23% | -35.55% |
Ownership & Short Interest
Insider Ownership
2.10%
Institutional Ownership
104.50%
Shares Short
4M
Short Ratio
8.26
Short % of Shares Outstanding
11.62%
Average 10-Day Volume
345K
Average 90-Day Volume
385K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BLFS's 52-week high and low?
- In the last 52 weeks, Biolife Solutions reached a high of $29.55 (on January 30, 2025) and a low of $19.10 (on April 9, 2025).
- What is the market cap and P/E ratio for BLFS?
- Curious about Biolife Solutions's size and valuation? Its market capitalization stands at 1.26B. When it comes to valuation, the P/E ratio (trailing twelve months) is -60.73, and the forward P/E (looking ahead) is -93.93.
- Does BLFS pay dividends? If so, what's the yield?
- As for dividends, Biolife Solutions isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Biolife Solutions's main competitors or similar companies to consider before investing?
When looking at Biolife Solutions, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Intuitive Surgical
ISRG163.82B Healthcare Medical Instruments & Supplies -7.57% 144.78% Becton, Dickinson
BDX55.18B Healthcare Medical Instruments & Supplies -18.00% -13.69% Lemaitre Vascular
LMAT2.01B Healthcare Medical Instruments & Supplies -2.81% 87.64% AtriCure
ATRC1.73B Healthcare Medical Instruments & Supplies 26.01% 4.78% Azenta
AZTA1.41B Healthcare Medical Instruments & Supplies -28.84% -17.23% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biolife Solutions Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Biolife Solutions's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -5.66%, the Debt to Equity ratio from the most recent quarter is 6.86, and its Gross Profit Margin stands at 64.64%.
- What is the recent revenue and earnings growth for BLFS?
- Looking at Biolife Solutions's growth, its revenue over the trailing twelve months (TTM) was $93M. Compared to the same quarter last year (YoY), quarterly revenue grew by 28.90%, and quarterly earnings saw a YoY growth of -10.26%.
- How much of BLFS stock is held by insiders and institutions?
- Wondering who owns Biolife Solutions stock? Company insiders (like executives and directors) hold about 2.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 104.50%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.